Abpro公司与Celltrion公司联合宣布，其核心多特异性抗体抗癌候选药物Abp-102（亦称为Ct-P72）已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。
这一重要进展标志着该创新疗法正式获准进入临床开发阶段，为后续的人体试验铺平道路。Abp-102/Ct-P72作为一种多特异性抗体，旨在通过靶向多个癌症信号通路，更有效地攻击肿瘤细胞。
此次IND获批是基于临床前研究显示的积极数据，证明了其在治疗特定癌症类型方面的潜力。两家公司计划迅速推进临床试验，以评估该药物在患者中的安全性和有效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.